154 related articles for article (PubMed ID: 38807673)
21. Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy: A case report.
Zhang L; Chen W; Wang XM; Zhang SQ
World J Clin Cases; 2022 Sep; 10(26):9398-9403. PubMed ID: 36159401
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
23. Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia.
Shima H; Kurosawa T; Oikawa H; Kobayashi H; Nishi E; Yamazaki F; Tomita K; Shimada H
Case Rep Oncol; 2022; 15(1):257-262. PubMed ID: 35431861
[TBL] [Abstract][Full Text] [Related]
24. Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma.
De Philippis C; Mannina D; Giordano L; Costantini E; Marcheselli S; Mariotti J; Sarina B; Taurino D; Santoro A; Bramanti S
Transplant Cell Ther; 2023 Jul; 29(7):429.e1-429.e6. PubMed ID: 36966874
[TBL] [Abstract][Full Text] [Related]
25. Cytokine release syndrome induced by pembrolizumab: A case report.
Zhang X; Fu Z; Yan C
Medicine (Baltimore); 2022 Dec; 101(49):e31998. PubMed ID: 36626467
[TBL] [Abstract][Full Text] [Related]
26. Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature.
Amlani A; Barber C; Fifi-Mah A; Monzon J
Oncologist; 2020 Jul; 25(7):e1120-e1123. PubMed ID: 32337758
[TBL] [Abstract][Full Text] [Related]
27. Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy.
Yoshimura A; Yamamoto Y; Nishikawa T; Fujita M; Inoue T; Kondo F; Hayashi T; Kawamura N; Nagahara A; Nakai Y; Nakayama M; Nishimura K
Int Cancer Conf J; 2024 Jan; 13(1):26-32. PubMed ID: 38187183
[TBL] [Abstract][Full Text] [Related]
28. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
29. Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report.
Sumi T; Koshino Y; Michimata H; Nagayama D; Watanabe H; Yamada Y; Chiba H
Transl Lung Cancer Res; 2022 Sep; 11(9):1973-1976. PubMed ID: 36248324
[TBL] [Abstract][Full Text] [Related]
30. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
[TBL] [Abstract][Full Text] [Related]
31. Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS.
Masucci C; Pepe S; La Rocca U; Zullino V; De Propris MS; Barberi W; Iori AP; Martelli S; Ruberto F; Martelli M; Di Rocco A
Front Oncol; 2023; 13():1171031. PubMed ID: 37397390
[TBL] [Abstract][Full Text] [Related]
32. [Effect of early tocilizumab intervention on patients with cytokine release syndrome following chimeric antigen receptor T cell therapy].
Zhou LL; Ye SG; Li P; Tang XC; Liang AB
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1022-1026. PubMed ID: 38503526
[No Abstract] [Full Text] [Related]
33. Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy.
Moriyama S; Fukata M; Yokoyama T; Ueno S; Nunomura T; Mori Y; Kato K; Miyamoto T; Akashi K
Front Cardiovasc Med; 2022; 9():848091. PubMed ID: 35387436
[TBL] [Abstract][Full Text] [Related]
34. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
35. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
[TBL] [Abstract][Full Text] [Related]
36. Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
38. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report.
Honjo O; Kubo T; Sugaya F; Nishizaka T; Kato K; Hirohashi Y; Takahashi H; Torigoe T
J Immunother Cancer; 2019 Apr; 7(1):97. PubMed ID: 30944043
[TBL] [Abstract][Full Text] [Related]
39. Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report.
Chen HH; Kuo CY; Ho CL; Chen YC
Medicine (Baltimore); 2023 Oct; 102(41):e35432. PubMed ID: 37832125
[TBL] [Abstract][Full Text] [Related]
40. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
Yao JM; Otoukesh S; Kim H; Yang D; Mokhtari S; Samara Y; Blackmon A; Arslan S; Agrawal V; Pourhassan H; Amanam I; Ball B; Koller P; Salhotra A; Becker P; Curtin P; Artz A; Aldoss I; Ali H; Stewart F; Smith E; Stein A; Marcucci G; Forman SJ; Nakamura R; Al Malki MM
Transplant Cell Ther; 2023 Aug; 29(8):515.e1-515.e7. PubMed ID: 37182736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
